Skip to content
Screener

Abbott ABT Finite Lived Intangible Assets - Gross

Finite Lived Intangible Assets - Gross at other companies

Haemonetics logo
HaemoneticsHAE
$803.3M+3.1%
Perrigo Company logo
Perrigo CompanyPRGO
$4.54B-7.9%
BellRing Brands logo
BellRing BrandsBRBR
$328.4M+0.1%
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$12.6B+13.0%
Gross profit$7.3B+15.6%
Operating income$1.7B-17.5%
Net income$928.0M-47.8%
EPS (diluted)$0.53-47.5%

Balance sheet

See full
Cash & equivalents$5.1B-26.6%
Total debt$32.6B+143%
Total equity$51.1B+1.1%
Total assets$109.22B+30.0%

Cash flow

See full
Operating cash flow$2.5B+21.5%
CapEx$497.0M-1.0%
Free cash flow$2.0B+28.9%

Valuation

See full
Market cap$182.92B-19.7%
Enterprise value$210.42B-10.2%
P/E33.7×+17.4×
P/S3.9×-1.4×

Profitability

See full
Gross margin56.6%+0.6pp
Operating margin15.8%-1.7pp
Net margin11.6%-20.8pp
FCF margin16.8%+1.1pp

Returns & leverage

See full
Return on equity10.7%-20.4pp
Debt / equity0.6×+0.4×
Current ratio1.4×-0.4×

Where this comes from

Reported directly by Abbott in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.

The source filing: Abbott’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:02 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050134

The gross amount of amortizable intangible assets, primarily product rights and technology, was $39.8 billion as of June 30, 2026, and $27.6 billion as of December 31, 2025. The gross amount of amortizable intangible assets increased by $12.3 billion in the first six months of 2026 due to the completion of the Exact Sciences acquisition. Accumulated amortization was $24.3 billion and $23.3 billion as of June 30, 2026, and December 31, 2025, respectively. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.6 billion in 2026, $2.3 billion in 2027, $1.8 billion in 2028, $1.7 billion in 2029, and $1.5 billion in 2030.

Item 1. Financial Statements and Supplementary Data

FAQ

What is Abbott's finite lived intangible assets - gross?
Abbott (ABT) reported finite lived intangible assets - gross of $39.8B in Q2 2026.
How has Abbott's finite lived intangible assets - gross changed year-over-year?
Abbott's finite lived intangible assets - gross increased by 44.2% year-over-year, from $27.6B to $39.8B.
What is the long-term trend for Abbott's finite lived intangible assets - gross?
Over 4 years (2021 to 2025), Abbott's finite lived intangible assets - gross has grown at a -0.1% compound annual growth rate (CAGR), from $27.7B to $27.6B.
What does finite lived intangible assets - gross mean?
This metric tracks the total historical cost of intangible assets that have a defined useful life, such as patents, software licenses, or customer relationships. It excludes assets with indefinite lives like certain trademarks or goodwill. It is a key indicator of the company's investment in intellectual property and intangible competitive advantages.

Ask your AI about Abbott's finite lived intangible assets - gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude